This is in agreement with a gene expression dataset previously reported by Lambertz et al.49 showing that in ALK-positive NB cell lines treated with 0.32 μM of the preclinical ALK inhibitor NVP-TAE684 for 6 h, PIM1 is significantly upregulated relative to vehicle-treated cells in 4/5 cell lines tested (Supplementary Fig. 8d). The gene discussed is PIM1; the disease is neuroblastoma.